PALVELLA THERAPEUTICS, INC. (PVLA) stock intrinsic value fair value estimate & owner earnings analysis

Palvella Therapeutics (formerly Pieris Pharmaceuticals, which merged into Palvella in 2024) is a late-stage clinical biotech developing topical treatments for rare skin diseases and vascular malformations. Its lead product candidate is QTORIN rapamycin, a 3.9% rapamycin gel, being developed for microcystic lymphatic malformations, cutaneous venous malformations and angiokeratomas. A second candidate, QTORIN pitavastatin for a skin condition called DSAP, is at the IND-enabling stage. The company has no approved product and reports no revenue, and it says it does not expect commercial revenue or operating cash flow in the next two years. What the numbers show: in 2025 the company lost $41.7 million and used $25.0 million of cash in operations. After removing working-capital timing (a $3.8 million inflow) and subtracting $6.4 million of stock compensation, owner earnings were about negative $35.2 million, or about negative $3.13 per share (negative $5.16 per share in 2024). There is no history of positive earnings to anchor a valuation on, and the company had no meaningful capital spending. Because the business was transformed by the 2024 merger, we look only at the years since. Progress that is real but not yet earnings: in February 2026 the company reported topline results from its Phase 3 SELVA trial in microcystic lymphatic malformations, and in December 2025 it announced positive topline results from the Phase 2 TOIVA trial in cutaneous venous malformations. QTORIN rapamycin holds Orphan Drug and Breakthrough Therapy designations for microcystic lymphatic malformations. The company plans to ask the FDA to agree to a rolling New Drug Application submission. However, the filing itself cautions that the FDA may not accept a baseline-controlled Phase 3 study as adequate for this condition. Approval, launch, pricing, uptake and eventual profits have all yet to happen. Financing: cash was $58.0 million at year-end 2025, and a February 2026 public offering added roughly $215.8 million net. The company states this funds operations for at least a year beyond the filing. That extends its runway but, under our method, cash raised is not counted as value beyond what the business can be shown to earn, and new share issuance dilutes existing holders. Bear, base and bull cases: we assign $0 per share to all three. A drug candidate that has not been approved, has no sales and has no contract or established earnings history does not meet the standard of evidence needed to credit any future profit, so nothing can be named and evidenced that produces owner earnings. The clinical data is encouraging, but approval and commercial results are events that have not yet happened. This is not a claim that the shares can never be worth more; it means the value depends entirely on future events, and those events cannot be underwritten today. A value built on approval would rest on speculation rather than on the business as it stands. What would change this view: FDA approval of QTORIN rapamycin followed by several quarters of reported sales showing positive cash earnings after stock compensation. We would then value it on the earnings actually produced. The margin-of-safety price today is $0 for that reason. Not reconciled: the company's cash-flow statement lists several working-capital items, and a few (payables, accrued expenses) were read from the statement itself rather than from structured data; the totals tie to the reported operating cash flow.